Two monoclonal antibodies targeting circulating IL-13 (dectrekumab and cendakimab) and a monoclonal antibody targeting the IL4/IL13 receptor (dupilumab) have been tested in patients with EoE. This evidence concerns the gene IL13 and eosinophilic esophagitis.